lenzetto 1.53 mg/dose solução para pulverização transdérmica
gedeon richter, plc. - estradiol - solução para pulverização transdérmica - 1.53 mg/dose - estradiol hemi-hidratado 17.56 mg/ml - estradiol - n/a - duração do tratamento: longa duração
etinilestradiol + gestodeno gestilla 0.02 mg + 0.075 mg comprimido revestido
gedeon richter, plc. - etinilestradiol + gestodeno - comprimido revestido - 0.02 mg + 0.075 mg - gestodeno 0.075 mg ; etinilestradiol 0.02 mg - gestodene and ethinylestradiol - genérico - duração do tratamento: longa duração
etinilestradiol + gestodeno dorinette 0.03 mg + 0.075 mg comprimido revestido
gedeon richter, plc. - etinilestradiol + gestodeno - comprimido revestido - 0.03 mg + 0.075 mg - gestodeno 0.075 mg ; etinilestradiol 0.03 mg - gestodene and ethinylestradiol - genérico - duração do tratamento: longa duração
etinilestradiol + gestodeno richter 0.03 mg + 0.075 mg comprimido revestido
gedeon richter, plc. - etinilestradiol + gestodeno - comprimido revestido - 0.03 mg + 0.075 mg - gestodeno 0.075 mg ; etinilestradiol 0.03 mg - gestodene and ethinylestradiol - genérico - duração do tratamento: longa duração
etinilestradiol + gestodeno gestilla 0.02 mg + 0.075 mg comprimido revestido
gedeon richter, plc. - etinilestradiol + gestodeno - comprimido revestido - 0.02 mg + 0.075 mg - gestodeno 0.075 mg ; etinilestradiol 0.02 mg - gestodene and ethinylestradiol - genérico - duração do tratamento: longa duração
etinilestradiol + gestodeno richter 0.03 mg + 0.075 mg comprimido revestido
gedeon richter, plc. - etinilestradiol + gestodeno - comprimido revestido - 0.03 mg + 0.075 mg - gestodeno 0.075 mg ; etinilestradiol 0.03 mg - gestodene and ethinylestradiol - genérico - duração do tratamento: longa duração
etinilestradiol + gestodeno dorinette 0.03 mg + 0.075 mg comprimido revestido
gedeon richter, plc. - etinilestradiol + gestodeno - comprimido revestido - 0.03 mg + 0.075 mg - gestodeno 0.075 mg ; etinilestradiol 0.03 mg - gestodene and ethinylestradiol - genérico - duração do tratamento: longa duração
zolsketil pegylated liposomal
accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.
acetato de clormadinona + etinilestradiol
adium s.a. - acetato de clormadinona, etinilestradiol - anticoncepcionais
estradiol + drospirenona
eurofarma laboratÓrios s.a. - estradiol hemi-hidratado, drospirenona - estrogenos assocs a outros farmacos exclusive androgenos